Xenon Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell XENE and other ETFs, options, and stocks.

About XENE

Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. 

CEO
Ian C. Mortimer
CEOIan C. Mortimer
Employees
370
Employees370
Headquarters
Burnaby, British Columbia
HeadquartersBurnaby, British Columbia
Founded
1996
Founded1996
Employees
370
Employees370

XENE Key Statistics

Market cap
4.60B
Market cap4.60B
Price-Earnings ratio
-12.67
Price-Earnings ratio-12.67
Dividend yield
Dividend yield
Average volume
3.35M
Average volume3.35M
High today
$59.00
High today$59.00
Low today
$54.93
Low today$54.93
Open price
$58.09
Open price$58.09
Volume
3.83M
Volume3.83M
52 Week high
$63.95
52 Week high$63.95
52 Week low
$26.74
52 Week low$26.74

Stock Snapshot

Xenon Pharmaceuticals(XENE) stock is priced at $55.23, giving the company a market capitalization of 4.6B. It carries a P/E multiple of -12.67.

On 2026-03-14, Xenon Pharmaceuticals(XENE) stock moved within a range of $54.93 to $59.00. With shares now at $55.23, the stock is trading +0.5% above its intraday low and -6.4% below the session's peak.

Trading volume for Xenon Pharmaceuticals(XENE) stock has reached 3.83M, versus its average volume of 3.35M.

Over the past 52 weeks, Xenon Pharmaceuticals(XENE) stock has traded between a high of $63.95 and a low of $26.74.

Over the past 52 weeks, Xenon Pharmaceuticals(XENE) stock has traded between a high of $63.95 and a low of $26.74.

XENE News

TipRanks 16h
Xenon Sets Date for 2026 Annual Shareholder Meeting

Xenon ( (XENE) ) has shared an update. Xenon Pharmaceuticals Inc. advised Canadian securities regulators on March 13, 2026 that it has set June 2, 2026 as the...

TipRanks 20h
Xenon’s X-TOLE2 Trial Completion Puts XEN1101 in Focus for Epilepsy Investors

Xenon Pharmaceuticals (XENE) announced an update on their ongoing clinical study. Xenon Pharmaceuticals Inc. (XENE) has completed its Phase 3 X-TOLE2 trial, of...

Simply Wall St 4d
Why Xenon Pharmaceuticals Is Up 38.4% After Strong Phase 3 Azetukalner Seizure Data And FDA Plans

Xenon Pharmaceuticals recently reported positive topline Phase 3 X-TOLE2 results for azetukalner in highly treatment‑resistant focal onset seizures, with both t...

Why Xenon Pharmaceuticals Is Up 38.4% After Strong Phase 3 Azetukalner Seizure Data And FDA Plans

Analyst ratings

100%

of 20 ratings
Buy
100%
Hold
0%
Sell
0%

More XENE News

TipRanks 5d
Xenon Pharmaceuticals announces $500M common shares offering

Xenon Pharmaceuticals (XENE) announced that it has commenced an underwritten public offering of $500M of its common shares, pursuant to its existing shelf regis...

Benzinga 5d
What's Going On With Biohaven Stock On Monday?

Biohaven Ltd (NYSE:BHVN) shares were trading higher on Monday during the premarket session at as high as $12.52, before falling. The movement comes in reaction...

What's Going On With Biohaven Stock On Monday?
TipRanks 5d
Xenon Pharmaceuticals announces Phase 3 X-TOLE2 study met primary endpoint

Xenon Pharmaceuticals (XENE) announced positive topline results from the Phase 3 X-TOLE2 study of azetukalner in focal onset seizures. The study met its primary...

People also own

Based on the portfolios of people who own XENE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.